Stylus Medicine
Stylus combines engineered recombinases with cell-targeted LNP delivery to create durable in vivo CAR-T through sequence-specific insertion. Its platform disclosure establishes preclinical research intent and mechanism, not patient benefit or demonstrated clinical safety.
Corporate information
- Company entity
- Stylus Medicine
- Headquarters / principal office
- Cambridge, Massachusetts, United States (official contact address) ↗
- Founded
- 2022 ↗
- Ownership / capital status
- PrivateSeries A and extension ↗
- Official corporate reference
- https://www.stylusmedicine.com/ ↗
- Latest financing / award identified
- 2025-05-13 · Series A extension · US$45 million ↗
- LinkedIn company page
- Independent company page not verified
Announcement date; not an additional US$85 million round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Stylus combines engineered recombinases with cell-targeted LNP delivery to create durable in vivo CAR-T through sequence-specific insertion. Its platform disclosure establishes preclinical research intent and mechanism, not patient benefit or demonstrated clinical safety.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Stylus Medicine — official page checked November 4, 2026
- Stylus Medicine launches with $85 million financing, including $45 million Series A extension